ReviewOncotarget2016
Optical imaging probes in oncology.
Review in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 59 citations in OpenAlex.
- Rapid assessment of target-binding fractions in molecular imaging agents using size-exclusion HPLC.EJNMMI radiopharmacy and chemistry · 2026Article
- Light Sensitive Liposomes: A Novel Strategy for Targeted Drug Delivery.Pharmaceutical nanotechnology · 2025Review
- Semi-automatic standardized analysis method to objectively evaluate near-infrared fluorescent dyes in image-guided surgery.Journal of biomedical optics · 2024Article
- Review
- Microcamera Visualisation System to Overcome Specular Reflections for Tissue Imaging.Micromachines · 2023Article
- Medical Imaging Technology and Imaging Agents.Advances in experimental medicine and biology · 2023Article
- Tumor Microenvironment and Immune Escape in the Time Course of Glioblastoma.Molecular neurobiology · 2022Article
- RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging.Molecular imaging and biology · 2022Article
- Macroscopic Fluorescence Lifetime Imaging for Monitoring of Drug-Target Engagement.Methods in molecular biology (Clifton, N.J.) · 2022Article
- A brief review of reporter gene imaging in oncolytic virotherapy and gene therapy.Molecular therapy oncolytics · 2021Review
- Review
- Review
- Applications of Nanoparticle-Antibody Conjugates in Immunoassays and Tumor Imaging.The AAPS journal · 2021Review
- Shortwave infrared emitting multicolored nanoprobes for biomarker-specific cancer imaging in vivo.BMC cancer · 2020Article
- Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Spatiotemporally controlled nano-sized third harmonic generation agents.Biomedical optics express · 2019Article
- Biomedical Imaging: Principles, Technologies, Clinical Aspects, Contrast Agents, Limitations and Future Trends in Nanomedicines.Pharmaceutical research · 2019Review
- The Continuing Evolution of Molecular Functional Imaging in Clinical Oncology: The Road to Precision Medicine and Radiogenomics (Part I).Molecular diagnosis & therapy · 2019Review
- Imaging of Red-Shifted Light From Bioluminescent Tumors Using Fluorescence by Unbound Excitation From Luminescence.Frontiers in bioengineering and biotechnology · 2019Article
- Development of [Pharmaceuticals (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a complex disease, characterized by alteration of different physiological molecular processes and cellular features. Keeping this in mind, the possibility of early identification and detection of specific tumor biomarkers by non-invasive approaches could improve early diagnosis and patient management.Different molecular imaging procedures provide powerful tools for detection and non-invasive characterization of oncological lesions. Clinical studies are mainly based on the use of computed tomography, nuclear-based imaging techniques and magnetic resonance imaging. Preclinical imaging in small animal models entails the use of dedicated instruments, and beyond the already cited imaging techniques, it includes also optical imaging studies. Optical imaging strategies are based on the use of luminescent or fluorescent reporter genes or injectable fluorescent or luminescent probes that provide the possibility to study tumor features even by means of fluorescence and luminescence imaging. Currently, most of these probes are used only in animal models, but the possibility of applying some of them also in the clinics is under evaluation.The importance of tumor imaging, the ease of use of optical imaging instruments, the commercial availability of a wide range of probes as well as the continuous description of newly developed probes, demonstrate the significance of these applications. The aim of this review is providing a complete description of the possible optical imaging procedures available for the non-invasive assessment of tumor features in oncological murine models. In particular, the characteristics of both commercially available and newly developed probes will be outlined and discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.